文献速递中枢神经肿瘤放疗放疗物理与技术

可解释人工智能辅助临床决策用于脑转移瘤放射外科剂量处方

Interpretable AI-assisted clinical decision making (CDM) for dose prescription in radiosurgery of brain metastases.
PubMed 文献 · Radiother Oncol · 2023-08-04

研究纳入2017至2021年接受放射外科治疗的152例脑转移瘤患者,构建融合CT影像与8项非影像临床参数的可解释卷积神经网络模型预测剂量分割方案。模型IM-2正确分类131例(86%),错分21例(14%);IM-10提供各输入相对权重解释,且模型输入重要性排序与医师自身排序高度一致。

要点

  • IM-2模型在19折交叉验证中正确分类131例(86%),错分21例(14%)。
  • IM-10模型给出各输入相对权重:靶区34%、靶区与危及器官关系35%、ECOG 6%、再治疗6%、其他部位转移6%等。
  • 模型解释的输入重要性排序与医师决策过程自身排序高度一致。

核心结论

  • 成功开发可解释卷积神经网络模型,利用CT影像和非影像临床参数预测脑转移瘤放射外科剂量处方。
  • 模型显示高预测准确率并提供决策过程解释,该解释经医师验证。
  • 可解释性使模型更透明,对模型未来在常规实践中辅助临床决策的采用至关重要。

研究设计与样本

  • 研究纳入2017至2021年接受放射外科治疗的152例脑转移瘤患者。
  • 提取CT影像、靶区和危及器官轮廓,以及8项非影像临床参数(年龄、脑转移数目、ECOG体能状态、有无症状、与手术的顺序、初治与再治疗、原发癌类型、其他部位转移)。
  • 构建基于CT数据和临床参数的三维卷积神经网络架构,融合三个输入:肿瘤大小形状位置、肿瘤与危及器官空间关系、临床参数。
  • 开发决策层融合两条独立路径(IM-2)、三条独立路径(IM-3)和十条独立路径(IM-10)的模型。
  • 以记录中的实际处方作为模型训练的真实标签,采用19折交叉验证评估模型性能,每折随机选取128例训练、16例验证、8例测试。

主要发现

  • 152例患者的剂量处方包括:48例1×24 Gy、48例1×20-22 Gy、32例3×9 Gy、24例5×6 Gy,由8名医师开具。
  • IM-2性能略优于IM-3和IM-10,正确分类131例(86%),错分21例(14%)。
  • IM-10提供最多的可解释性,各输入相对权重为:靶区34%、靶区与危及器官关系35%、ECOG 6%、再治疗6%、其他部位转移6%、脑转移数目3%、有症状3%、术前或术后3%、原发癌类型2%、年龄2%。
  • 模型解释的输入重要性排序与医师在决策过程中的自身排序高度一致。

关键数值与推荐

  • IM-2模型正确分类131例(86%),错分21例(14%)。
  • IM-10模型各输入相对权重:靶区34%、靶区与危及器官关系35%、ECOG 6%、再治疗6%、其他部位转移6%、脑转移数目3%、有症状3%、术前或术后3%、原发癌类型2%、年龄2%。

临床怎么用

  • 原文结论未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: AI modeling physicians' clinical decision-making (CDM) can improve the efficiency and accuracy of clinical practice or serve as a surrogate to provide initial consultations to patients seeking secondary opinions. In this study, we developed an interpretable AI model that predicts dose fractionation for patients receiving radiation therapy for brain metastases with an interpretation of its decision-making process. MATERIALS/METHODS: 152 patients with brain metastases treated by radiosurgery from 2017 to 2021 were obtained. CT images and target and organ-at-risk (OAR) contours were extracted. Eight non-image clinical parameters were also extracted and digitized, including age, the number of brain metastasis, ECOG performance status, presence of symptoms, sequencing with surgery (pre- or post-operative radiation therapy), de novo vs. re-treatment, primary cancer type, and metastasis to other sites. 3D convolutional neural networks (CNN) architectures with encoding paths were built based on the CT data and clinical parameters to capture three inputs: (1) Tumor size, shape, and location; (2) The spatial relationship between tumors and OARs; (3) The clinical parameters. The models fuse the features extracted from these three inputs at the decision-making level to learn the input independently to predict dose prescription. Models with different independent paths were developed, including models combining two independent paths (IM-2), three independent paths (IM-3), and ten independent paths (IM-10) at the decision-making level. A class activation score and relative weighting were calculated for each input path during the model prediction to represent the role of each input in the decision-making process, providing an interpretation of the model prediction. The actual prescription in the record was used as ground truth for model training. The model performance was assessed by 19-fold cross-validation, with each fold consisting of randomly selected 128 training, 16 validation, and 8 testing subjects. RESULT: The dose prescriptions of 152 patient cases included 48 cases with 1 × 24 Gy, 48 cases with 1 × 20-22 Gy, 32 cases with 3 × 9 Gy, and 24 cases with 5 × 6 Gy prescribed by 8 physicians. IM-2 achieved slightly superior performance than IM-3 and IM-10, with 131 (86%) patients classified correctly and 21 (14%) patients misclassified. IM-10 provided the most interpretability with a relative weighting for each input: target (34%), the relationship between target and OAR (35%), ECOG (6%), re-treatment (6%), metastasis to other sites (6%), number of brain metastases (3%), symptomatic (3%), pre/post-surgery (3%), primary cancer type (2%), age (2%), reflecting the importance of the inputs in decision making. The importance ranking of inputs interpreted from the model also matched closely with a physician's own ranking in the decision process. CONCLUSION: Interpretable CNN models were successfully developed to use CT images and non-image clinical parameters to predict dose prescriptions for brain metastases patients treated by radiosurgery. Models showed high prediction accuracy while providing an interpretation of the decision process, which was validated by the physician. Such interpretability makes the model more transparent, which is crucial for the future clinical adoption of the models in routine practice for CDM assistance.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Cao Y, Kunaprayoon D, Ren L, et al. Interpretable AI-assisted clinical decision making (CDM) for dose prescription in radiosurgery of brain metastases. Radiother Oncol. 2023. PMID: 37543055. doi:10.1016/j.radonc.2023.109842

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。